NCT04921995 (RETICULA-NPC) is a Phase 2 clinical trial of Tislelizumab in Recurrent Nasopharyngeal Carcinoma, sponsored by Fudan University.

Who is sponsoring NCT04921995?

NCT04921995 is sponsored by Fudan University.

What drugs are being tested in NCT04921995?

Interventions in NCT04921995: Tislelizumab.

What condition does NCT04921995 study?

NCT04921995 studies Recurrent Nasopharyngeal Carcinoma, Unresectable Nasopharyngeal Carcinoma, Chemotherapy Effect, Immunotherapy, Stereotactic Body Radiation Therapy (SBRT).

Is NCT04921995 still recruiting?

NCT04921995 is currently status unknown. Last updated 4 April 2022.

Last reviewed 2022-04-04 · How we verify

NCT04921995: RETICULA-NPC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma

Status unknown Phase 2 Last updated 4 April 2022

What this trial tests

Phase 2 trial testing Tislelizumab in Recurrent Nasopharyngeal Carcinoma in 40 participants. Status unknown.

Timeline

15 April 2019

Primary endpoint
30 October 2022

30 June 2024

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	15 April 2019
Primary completion	30 October 2022
Estimated completion	30 June 2024
Sites	1 location across China

Drugs / interventions tested

Tislelizumab (TISLELIZUMAB) — full drug profile →

Conditions studied

Recurrent Nasopharyngeal Carcinoma — all drugs for Recurrent Nasopharyngeal Carcinoma →
Unresectable Nasopharyngeal Carcinoma — all drugs for Unresectable Nasopharyngeal Carcinoma →
Chemotherapy Effect — all drugs for Chemotherapy Effect →
Immunotherapy — all drugs for Immunotherapy →

Sponsor

Fudan University

Who can join

Adults 15 to 90, any sex, with Recurrent Nasopharyngeal Carcinoma or Unresectable Nasopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, multi-center, phase II trial to evaluate the safety and efficacy of postponing or omitting re-irradiation after systemic therapy with tislelizumab and chemotherapy in patients with unresectable recurrent loco-regionally advanced nasopharyngeal carcinoma. Patients who did not respond to or progressed on another ICI are allowed to receive tislelizumab rechallenge as a subgroup.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Tislelizumab

Trials testing the same drug.

NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting
NCT07290985 — AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas · Phase 2 · not yet recruiting
NCT07518706 — Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin · Phase 2 · not yet recruiting

Other recruiting trials for Recurrent Nasopharyngeal Carcinoma

Currently open trials in the same condition.

NCT07412314 — Proton Therapy for Recurrent Nasopharyngeal Carcinoma · NA · recruiting
NCT06029270 — Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Meta · Phase 2 · recruiting
NCT06235203 — Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC · Phase 3 · recruiting
NCT06228079 — Adjuvant vs Surgery Only in Early-stage Recurrent NPC · Phase 3 · recruiting
NCT05904080 — Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, · Phase 2 · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04921995 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 4 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04921995.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing